• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Low- vs High-Dose 5-FU in Triplet Chemotherapy Plus Bevacizumab for Patients With Colorectal Cancer.

作者信息

Chapin William J, Hwang Wei-Ting, Mamtani Ronac, O'Hara Mark H

机构信息

Division of Hematology and Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia.

Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia.

出版信息

JAMA Netw Open. 2024 Jul 1;7(7):e2424855. doi: 10.1001/jamanetworkopen.2024.24855.

DOI:10.1001/jamanetworkopen.2024.24855
PMID:39083278
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11292450/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fe1b/11292450/fddd1516b985/jamanetwopen-e2424855-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fe1b/11292450/fddd1516b985/jamanetwopen-e2424855-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fe1b/11292450/fddd1516b985/jamanetwopen-e2424855-g001.jpg

相似文献

1
Low- vs High-Dose 5-FU in Triplet Chemotherapy Plus Bevacizumab for Patients With Colorectal Cancer.低剂量与高剂量5-氟尿嘧啶用于三联化疗联合贝伐单抗治疗结直肠癌患者的疗效比较
JAMA Netw Open. 2024 Jul 1;7(7):e2424855. doi: 10.1001/jamanetworkopen.2024.24855.
2
Panitumumab-based maintenance after oxaliplatin discontinuation in metastatic colorectal cancer: A retrospective analysis of two randomised trials.基于帕尼单抗的奥沙利铂停药后维持治疗转移性结直肠癌：两项随机试验的回顾性分析。
Int J Cancer. 2019 Jul 15;145(2):576-585. doi: 10.1002/ijc.32110. Epub 2019 Jan 24.
3
Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.一项II期随机试验，比较贝伐单抗联合氟尿嘧啶（FU）/亚叶酸钙（LV）与单纯FU/LV用于转移性结直肠癌患者的疗效。
J Clin Oncol. 2003 Jan 1;21(1):60-5. doi: 10.1200/JCO.2003.10.066.
4
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. upfront FOLFOXIRI 联合贝伐珠单抗和进展后再引入与 mFOLFOX6 联合贝伐珠单抗后序贯 FOLFIRI 联合贝伐珠单抗治疗转移性结直肠癌患者（TRIBE2）：一项多中心、开放标签、3 期、随机、对照临床试验。
Lancet Oncol. 2020 Apr;21(4):497-507. doi: 10.1016/S1470-2045(19)30862-9. Epub 2020 Mar 9.
5
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.FOLFOXIRI 联合贝伐珠单抗对比 FOLFIRI 联合贝伐珠单抗一线治疗转移性结直肠癌患者：开放标签、3 期 TRIBE 研究的总生存更新及分子亚组分析。
Lancet Oncol. 2015 Oct;16(13):1306-15. doi: 10.1016/S1470-2045(15)00122-9. Epub 2015 Aug 31.
6
Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial.KRAS 野生型转移性结直肠癌一线进展后继续贝伐珠单抗或西妥昔单抗联合化疗：UNICANCER PRODIGE18 随机临床试验
JAMA Oncol. 2019 Jan 1;5(1):83-90. doi: 10.1001/jamaoncol.2018.4465.
7
Protocol of a randomised phase III clinical trial of sequential capecitabine or 5-fluorouracil plus bevacizumab (Cape/5-FU-Bmab) to capecitabine or 5-fluorouracil plus oxaliplatin plus bevacizumab (CapeOX/mFOLFOX6-Bmab) versus combination CapeOX/mFOLFOX6-Bmab in advanced colorectal cancer: the C-cubed (C3) study.一项关于晚期结直肠癌的随机 III 期临床试验方案：序贯卡培他滨或 5-氟尿嘧啶加贝伐单抗（Cape/5-FU-Bmab）对比卡培他滨或 5-氟尿嘧啶加奥沙利铂加贝伐单抗（CapeOX/mFOLFOX6-Bmab）与联合 CapeOX/mFOLFOX6-Bmab 的 C 立方（C3）研究
BMJ Open. 2016 Jun 2;6(6):e011454. doi: 10.1136/bmjopen-2016-011454.
8
Use of FOLFOXIRI Plus Bevacizumab and Subsequent Therapies in Metastatic Colorectal Cancer: An Age-Stratified Analysis.FOLFOXIRI 联合贝伐珠单抗及后续治疗转移性结直肠癌的年龄分层分析。
Clin Colorectal Cancer. 2024 Sep;23(3):258-271.e1. doi: 10.1016/j.clcc.2024.05.001. Epub 2024 May 6.
9
A phase II study of bevacizumab with modified OPTIMOX1 as first-line therapy for metastatic colorectal cancer: the TCOG-GI 0802 study.一项关于贝伐单抗联合改良OPTIMOX1方案作为转移性结直肠癌一线治疗的II期研究：TCOG-GI 0802研究
Invest New Drugs. 2015 Aug;33(4):954-62. doi: 10.1007/s10637-015-0239-1. Epub 2015 May 5.
10
Pharmacokinetic dose adjustment of 5-FU in modified FOLFOX7 plus bevacizumab for metastatic colorectal cancer in Japanese patients: a-JUST phase II clinical trial.在日本患者中，改良FOLFOX7联合贝伐单抗治疗转移性结直肠癌时5-氟尿嘧啶的药代动力学剂量调整：a-JUST II期临床试验
Cancer Chemother Pharmacol. 2016 Dec;78(6):1253-1261. doi: 10.1007/s00280-016-3184-6. Epub 2016 Nov 2.

引用本文的文献

1
CF10 Displayed Improved Activity Relative to 5-FU in a Mouse CRLM Model Under Conditions of Physiological Folate.在生理叶酸条件下的小鼠结直肠癌肝转移模型中，CF10相对于5-氟尿嘧啶表现出更高的活性。
Cancers (Basel). 2025 Aug 23;17(17):2739. doi: 10.3390/cancers17172739.

本文引用的文献

1
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. upfront FOLFOXIRI 联合贝伐珠单抗和进展后再引入与 mFOLFOX6 联合贝伐珠单抗后序贯 FOLFIRI 联合贝伐珠单抗治疗转移性结直肠癌患者（TRIBE2）：一项多中心、开放标签、3 期、随机、对照临床试验。
Lancet Oncol. 2020 Apr;21(4):497-507. doi: 10.1016/S1470-2045(19)30862-9. Epub 2020 Mar 9.
2
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.FOLFOXIRI 联合贝伐珠单抗对比 FOLFIRI 联合贝伐珠单抗一线治疗转移性结直肠癌患者：开放标签、3 期 TRIBE 研究的总生存更新及分子亚组分析。
Lancet Oncol. 2015 Oct;16(13):1306-15. doi: 10.1016/S1470-2045(15)00122-9. Epub 2015 Aug 31.
3
Potential regional differences for the tolerability profiles of fluoropyrimidines.氟嘧啶耐受性特征的潜在区域差异。
J Clin Oncol. 2008 May 1;26(13):2118-23. doi: 10.1200/JCO.2007.15.2090.